CR Sanjiu Reports Strong Mid-Year Financial Growth
Company Announcements

CR Sanjiu Reports Strong Mid-Year Financial Growth

China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.

CR Sanjiu, a subsidiary of China Resources Pharmaceutical Group Ltd., has reported a significant rise in its financial performance for the first half of 2024, with a 27.77% increase in net profit for shareholders and a 33.36% growth in net cash flow from operating activities. Total assets and net assets have respectively risen by 1.37% and 5.20%, reflecting a solid growth trajectory for the company. Investors are cautioned to consider the unaudited nature of these results and to consult the full interim report for a comprehensive understanding.

For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskChina Resources Pharmaceutical Completes Green Cross HK Acquisition
TipRanks HongKong Auto-Generated NewsdeskChina Resources Subsidiary Reports Revenue Surge Amid Cash Challenges
TipRanks HongKong Auto-Generated NewsdeskChina Resources Sanjiu Reports Rising Profits Despite Cash Decline
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App